Rubio report outlines Chinese threat to U.S. biotech industry

Biotech opportunities for foreign companies doing business in China may be short-lived as the country builds its domestic biosimilars industry, according to a report released Tuesday by Sen. Marco Rubio (R-Fla.).

The report, "Made in China 2025 and the Future of American Industry," was issued through the U.S. Senate Small Business and Entrepreneurship Committee, which Rubio chairs...